Used in the treatment of multiple sclerosis, this antibody targets LINGO-1, a protein that inhibits neuronal repair and myelination in the central nervous system. By blocking LINGO-1, it promotes remyelination of damaged nerve fibers, potentially restoring nerve function and slowing disease progression. Investigated in clinical trials for relapsing forms of multiple sclerosis and acute optic neuritis, it aims to improve neurological outcomes by supporting the repair of myelin, which is lost during autoimmune attacks. Its application focuses on neuroprotection and repair, offering a regenerative approach rather than just immunosuppression.